NO20064499L - Crystalline composition containing escitalopram oxalate - Google Patents

Crystalline composition containing escitalopram oxalate

Info

Publication number
NO20064499L
NO20064499L NO20064499A NO20064499A NO20064499L NO 20064499 L NO20064499 L NO 20064499L NO 20064499 A NO20064499 A NO 20064499A NO 20064499 A NO20064499 A NO 20064499A NO 20064499 L NO20064499 L NO 20064499L
Authority
NO
Norway
Prior art keywords
escitalopram oxalate
particles
composition containing
crystalline
crystalline composition
Prior art date
Application number
NO20064499A
Other languages
Norwegian (no)
Inventor
Ken Liljegren
Rikke Eva Humble
Kim Bojstrup Jensen
Troels Volsgaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34921251&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064499(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20064499L publication Critical patent/NO20064499L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelse bringer for dagen krystallinske partikler av escitalopram-oksalat som enten har en bred partikkelstørrelsesfordeling eller omfatter minst 0,01 % (vekt/vekt) Z-4-(4-dimetylamino-1-(4-fluorfenyl)-but-1-enyl)-3-hydroksymetyl-benzonitril, partiklene er passende for anvendelse i direkte sammentrykking. Videre bringer oppfinnelsen for dagen en ny farmasøytisk enhetsdoseringsform inneholdende slike krystallinske partikler av escitalopram-oksalat samt fremgangsmåter for fremstilling av slike krystallinske partikler av escitalopram-oksalat Til sist tilveiebringer oppfinnelsen en fremgangsmåte for reduksjon av mengden av hydroksylinneholdende forurensninger i en løsning av citalopram eller escitalopram.The present invention brings about crystalline escitalopram oxalate particles which either have a wide particle size distribution or comprise at least 0.01% (w / w) Z-4- (4-dimethylamino-1- (4-fluorophenyl) but-1 -enyl) -3-hydroxymethyl-benzonitrile, the particles are suitable for use in direct compression. Furthermore, the present invention provides a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as processes for preparing such crystalline particles of escitalopram oxalate.

NO20064499A 2004-03-05 2006-10-04 Crystalline composition containing escitalopram oxalate NO20064499L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55090904P 2004-03-05 2004-03-05
DKPA200400382 2004-03-05
PCT/DK2005/000115 WO2005084643A1 (en) 2004-03-05 2005-02-21 Crystalline composition containing escitalopram oxalate

Publications (1)

Publication Number Publication Date
NO20064499L true NO20064499L (en) 2006-12-04

Family

ID=34921251

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064499A NO20064499L (en) 2004-03-05 2006-10-04 Crystalline composition containing escitalopram oxalate

Country Status (9)

Country Link
EP (1) EP1732514A1 (en)
JP (1) JP2007526262A (en)
AU (1) AU2005218713B2 (en)
BR (1) BRPI0508266A (en)
CA (1) CA2558198A1 (en)
EA (1) EA200601641A1 (en)
NO (1) NO20064499L (en)
NZ (1) NZ549100A (en)
WO (1) WO2005084643A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
EP2086509A1 (en) * 2006-10-20 2009-08-12 Ratiopharm GmbH Escitalopram and solid pharmaceutical composition comprising the same
EP2116231A1 (en) * 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
JP2018016569A (en) * 2016-07-26 2018-02-01 株式会社トクヤマ Production method of (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate
JP6554245B1 (en) * 2019-01-31 2019-07-31 第一工業製薬株式会社 2,2'-bis (2-hydroxyethoxy) -1,1'-binaphthalene powder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (en) * 2001-06-25 2004-03-03 Lundbeck & Co As H PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND / OR OF THE S- OR R-CITALOPRAM THROUGH THE SEPARATION OF A MIXING OF R- AND S-CITALOPRAM
IL159326A0 (en) * 2001-07-31 2004-06-01 Lundbeck & Co As H Crystalline composition containing escitalopram
PE20040991A1 (en) * 2002-08-12 2004-12-27 Lundbeck & Co As H SEPARATION OF INTERMEDIARIES FOR THE PREPARATION OF ESCITALOPRAM
MXPA05005772A (en) * 2002-12-23 2005-08-16 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof.
TR200504022T1 (en) * 2003-03-24 2006-08-21 Hetero Drugs Limited New liquid crystal forms of (S) -sitalopram oxalate.

Also Published As

Publication number Publication date
JP2007526262A (en) 2007-09-13
CA2558198A1 (en) 2005-09-15
EP1732514A1 (en) 2006-12-20
AU2005218713A1 (en) 2005-09-15
NZ549100A (en) 2010-02-26
AU2005218713B2 (en) 2009-11-19
BRPI0508266A (en) 2007-07-31
WO2005084643A1 (en) 2005-09-15
EA200601641A1 (en) 2006-12-29

Similar Documents

Publication Publication Date Title
MX2007012936A (en) Dihydrobenzofuran derivatives and uses thereof.
MXPA05010682A (en) Novel compounds.
BRPI0512326A (en) compositions comprising amphotericin b, methods and systems
EA200700566A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING LEVETRIACETES, AND METHODS OF THEIR RECEIVING
MY145609A (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
TW200510303A (en) Novel compounds
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
SE0302760D0 (en) New compounds
SE0202241D0 (en) Novel Compounds
TW200745003A (en) Novel compounds
WO2009102893A3 (en) Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors
NO20064499L (en) Crystalline composition containing escitalopram oxalate
AR111570A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY SELEXIPAG
PH12020550683A1 (en) Novel bradykinin b2 receptor antagonists
TW200800967A (en) Benzimidazole thiophene compounds
SI1506185T1 (en) Compounds and their use as inhibitors of 5-ht
EA201000752A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING EZETIMIB
NO20071314L (en) Peptidic vasopressin receptor agonists
JO2849B1 (en) Fast -Dissociating Dopamine 2 Receptor Antagonists
SG10201906942PA (en) Piperidine cxcr7 receptor modulators
EA200601194A1 (en) NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR
MXPA05013151A (en) 3-fluoro-piperidines as nmda/nr2b antagonists.
MX2022004882A (en) Pharmaceutical composition comprising selexipag.
ZA202206266B (en) Pd-l1 antagonist compound

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application